TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 154.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can TG Therapeutics (TGTX) Climb 155% to Reach the Level Wall Street Analysts Expect?

Lantheus Holdings

QuidelOrtho Corp

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

3 Medical Products Stocks Navigating Industry Challenges (Revised)

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TG Therapeutics (TGTX) Upgraded to Buy: Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 151.2% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does TG Therapeutics (TGTX) Have the Potential to Rally 151% as Wall Street Analysts Expect?

TG Therapeutics (NASDAQ:TGTX ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Jenna Bosco - Investor Relations Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H. C. Wainwright Chris Howerton - Jefferies Matt Kaplan - Ladenburg Thalmann Eric Joseph - JPMorgan Sahil Kazmi - B.

TG Therapeutics (TGTX) Q3 2022 Earnings Call Transcript

Why Shares of TG Therapeutics Climbed 59.9% This Week

The company had a nugget of good news in its third-quarter report.

Why TG Therapeutics' Shares Rose 63.37% on Thursday

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.21% and 97.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates

Conference call to be held today, November 10, 2022 at 8:30 AM ET Conference call to be held today, November 10, 2022 at 8:30 AM ET

TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Conference call to be held Thursday, November 10, 2022 at 8:30 AM ET Conference call to be held Thursday, November 10, 2022 at 8:30 AM ET

TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Links to each of the presentations are included below.

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 26 – 28, 2022, in Amsterdam, the Netherlands. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at https://journals.sagepub.com/doi/epub/10.1177/13524585221123687. Details of the presentations are outlined below. PRESENTATIONS: Poster Presentation Title: Disability Changes in the Absence of Relapse in the Phase 3 ULTIMATE I and II Studies of ublituximab Versus teriflunomide in Participants With Relapsing Multiple Sclerosis

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

As a turnaround play, TG Therapeutics has an extremely high-risk profile with correspondingly high rewards. The lead medicine ublituximab is going to the FDA for a potential approval this December as a treatment for the devastating condition, multiple sclerosis.

TG Therapeutics: Elucidating The Upcoming Binary

2022 has been a terrible year for a once-promising TGTX. Maybe the FDA decision on December 28 will help us break even.

TG Therapeutics: We Are Just Hanging In There

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) and certain of its officers, on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired TG Therapeutics securities between January 15, 2020 and May 31, 2022, both dates inclusive (the “Class Period”). Such i

Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds TG Therapeutics, Inc. (TGTX) Investors of Class Action and Last Few Hours to Actively Participate

Los Angeles, California--(Newsfile Corp. - September 16, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TG Therapeutics, Inc. ("TG Therapeutics" or "the Company") (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 16, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of TG Therapeutics, Inc. (NASDAQ: TGTX).

TGTX SHAREHOLDER ALERT: Jakubowitz Law Reminds TG Therapeutics Shareholders of a Lead Plaintiff Deadline of September 16, 2022

NEW YORK , Sept. 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TG Therapeutics, Inc. (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, both dates inclusive (the "Class Period"), of the important September 16, 2022 lead plaintiff deadline.

TGTX DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - TGTX

Los Angeles, California--(Newsfile Corp. - September 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TG Therapeutics, Inc. ("TG Therapeutics" or "the Company") (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 15, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX) of a class action securities lawsuit.

TGTX LAWSUIT ALERT: Levi & Korsinsky Notifies TG Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - September 14, 2022) - Levi & Korsinsky, LLP notifies investors in TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX) of a class action securities lawsuit.The lawsuit on behalf of TG Therapeutics investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain TG Therapeutics, Inc.

TG Therapeutics Class Action: Levi & Korsinsky Reminds TG Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 16, 2022 - TGTX

Los Angeles, California--(Newsfile Corp. - September 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TG Therapeutics, Inc. ("TG Therapeutics" or "the Company") (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

FRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 14, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TG Therapeutics, Inc..

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of TG Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 16, 2022 - (NASDAQ: TGTX)

New York, New York--(Newsfile Corp. - September 13, 2022) - Levi & Korsinsky, LLP notifies investors in TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX) of a class action securities lawsuit.The lawsuit on behalf of TG Therapeutics investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain TG Therapeutics, Inc.

TG Therapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 16, 2022 to Discuss Your Rights - TGTX

New York, New York--(Newsfile Corp. - September 13, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TG Therapeutics, Inc. (NASDAQ: TGTX) alleging that the Company violated federal securities laws.Class Period: January 15, 2020 to May 31, 2022Lead Plaintiff Deadline: September 16, 2022No obligation or cost to you.Learn more about your recoverable losses in TGTX:https://www.kleinstocklaw.com/pslra-1/tg-therapeutics-loss-submission-form?id=31666&from=5

TGTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 16, 2022 in the Class Action Filed on Behalf of TG Therapeutics, Inc. Limited Shareholders

News for TG Therapeutics Stock (TGTX)